ASH develops and publishes evidence-based clinical practice guidelines to help practicing hematologists and other clinicians improve the quality of patient care. ASH’s guideline development is overseen by the ASH Guideline Oversight Subcommittee, which reports to the ASH Committee on Quality. This subcommittee selects guideline topics, vets and appoints individuals to serve on guideline panels, and determines policies and procedures for guideline development.
Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment. ASH also endorses other clinical guidelines of relevance to practicing hematologists.
A collaboration with the McMaster University GRADE Center, 10 guidelines will be published in 2018 on the prevention, diagnosis, and treatment of venous thromboembolism.
ASH is collaborating with ISTH, NHF, WFH, and the University of Kansas Medical Center to develop two guidelines on the diagnosis and management of von Willebrand disease.
Five new guidelines on the management of acute and chronic complications of sickle cell disease are currently in development, with publication expected in 2019.
This ASH-ASCO guideline features the latest research and guidelines about the use of epoetin for the treatment of cancer-related anemia.
Published in 2011, this guideline is an evidence-based analysis of the diagnosis and management of idiopathic thrombocytopenia. A revision of this guideline is expected in 2018.
Published in partnership with the College of American Pathologists, this guideline addresses the initial work-up of acute leukemia.
Learn about ASH’s new guideline collaboration with the American Society for Clinical Pathology and the College of American Pathologists on laboratory workup of lyphoma.
Von Willebrand Disease (VWD)
Guidelines on the Diagnosis and Management of VWD
The American Society of Hematology (ASH), in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH), is developing clinical practice guidelines on the diagnosis and management of VWD. Publication of the guidelines is anticipated in 2020.
VWD is a rare disease, but it is one of the most common bleeding disorders in the United States, affecting up to 1 percent of the general population. According to a 2015 report by the NHF, there is variation in clinical practice in both the diagnosis and management of the disease.
As part of the initial phase of guideline development, a stakeholder survey has been created to help determine the key topics to include in the guidelines. We are inviting all individuals with VWD, those who care for someone with VWD, and clinicians and other health care professionals who treat people with VWD to take part in this survey. Your responses will inform the development of the specific questions and outcomes covered by the VWD guidelines.
The survey is being conducted by the University of Kansas Medical Center, which is leading the methodology of the guideline process and evidence synthesis.
If you have any questions or concerns, please contact firstname.lastname@example.org to top
Sickle Cell Disease (SCD)
ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease (SCD). Topics to be addressed include pain, cerebrovascular disease, cardiopulmonary and kidney disease, stem cell transplantation, and transfusion support.
Publication of the five guidelines is anticipated in 2019.back to top
Epoetin and Darbepoetin
"ASH-American Society of Clinical Oncology (ASCO) 2010 clinical practice guideline update on the use of epoetin and darbepoetin"
Published in Blood on November 18, 2010, this guideline features the latest research and evidence-based clinical guidelines about the use of epoetin for the treatment of cancer-related anemia.back to top
Clinical Practice Guideline on the Evaluation and Management of ITP
Published in Blood on April 21, 2011, this guideline is an evidence-based analysis of the diagnosis and management of idiopathic thrombocytopenia developed by a panel of specialists sponsored by ASH.
In 2015, ASH convened an expert panel to revise the 2011 guidelines. Systematic evidence review and methodological support for these guidelines is provided by the University of Oklahoma Health Sciences Center. Publication of the revised guidelines is expected in 2018.back to top
Initial Workup of Acute Leukemia
"Initial Diagnostic Work-up of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology"
On February 22, 2017, the College of American Pathologists (CAP) and the American Society of Hematology (ASH) published an evidence-based guideline that addresses the initial work-up of acute leukemia. The guideline was published in an early online edition of the Archives of Pathology and Laboratory Medicine.
The guideline defines the recommended clinical information and laboratory testing needed for proper diagnosis, with the goal of optimal prognosis of pediatric and adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and mixed-phenotype acute leukemia (MPAL).
ASH and CAP have provided a mini-review that explains the impetus for the guideline and outlines the
The guideline recommendations are also available as a printed pocket
guide and in the ASH Pocket Guides app (available on iOS and Android).back to top
Laboratory Workup of Lymphoma
The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) are collaborating to develop a practice guideline on the laboratory workup of patients with suspected lymphoma.
An expert panel formed in 2017 includes both hematopathologists and clinical hematologists representing the three collaborating organizations. The guideline will address laboratory ordering and communications, specimen handling, and diagnostic and prognostic testing including molecular testing.
back to top